KRASG12C-Inhibition bei Karzinomen

KRASG12C inhibition in tumor therapy

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.

    Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ (2014) Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 13:828–851. https://doi.org/10.1038/nrd4389

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K‑Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503:548–551. https://doi.org/10.1038/nature12796

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Canon J, Rex K, Saiki AY et al (2019) The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumor immunity. Nature 575:217–223. https://doi.org/10.1038/s41586-019-1694-1

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to PD Dr. med. Hakan Alakus.

Ethics declarations

Interessenkonflikt

H. Alakus, M. Hartmann, D. Ast und C. Bruns geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Alakus, H., Hartmann, M., Ast, D. et al. KRASG12C-Inhibition bei Karzinomen. Onkologe (2020). https://doi.org/10.1007/s00761-020-00870-y

Download citation